Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib. - ppt video online download
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma | Future Oncology
PDF) A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma
Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib. - ppt video online download
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
E-Learning Metastatic Melanoma Treatment
Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma | Future Oncology
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
E-Learning Metastatic Melanoma Treatment
PDF) Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis
Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy - ScienceDirect
Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib. - ppt video online download
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. - Abstract - Europe PMC
Drug-Like Small Molecules That Inhibit Expression of the Oncogenic MicroRNA-21 | ACS Chemical Biology
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. - Abstract - Europe PMC
The Future of Melanoma Therapy
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis - ScienceDirect
E-Learning Metastatic Melanoma Treatment
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma Share Your Story
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
